The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Open accessAbstract
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood. Recent studies revealed that response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, several critical proteins including CMTM4, CMTM6, GSK3β, CSN5, CDK4, CDK6, and palmitoylated B3GNT3 have been shown to affect post-translational PD-L1 stability31–36.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the Cullin 3-SPOP E3-ligase complex can directly ubiquitinate PD-L1 in a cell-cycle dependent manner, leading to its degradation [15].”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“First, as previously described [15], perturbation of the CUL3-SPOP complex interferes with the ubiquitination of PD-L1, directly enhancing its stability and protein expression level.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [15]
In the citing paper
“CDK4 was shown to have kinase activity towards SPOP, a cullin 3 E3 ubiquitin ligase adaptor protein that can interact with PD-L1 (Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Treatment with palbociclib inhibits SPOP phosphorylation, promoting its degradation and blocking PD-L1 proteasome mediated degradation.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
In the citing paper
“Combining palbociclib with a PD-1 blockade enhanced tumor regression and improved overall survival in mouse xenograft models of colon adenocarcinoma (Deng et al., 2017; Zhang et al., 2018).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Zhang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A. A., Ahn, J., Akbani, R., Ally, A., Amin, S. B., Andry, C., Annala, M., Aprikian, A. G., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,126
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationTaxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P. P., White, T. A., Stojanov, P., Allen, E. M. V., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,550
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 64
Papadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 68
Deregulation of SPOP in Cancer
Zhang, H., Jin, X., & Huang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2801 · Cited by 66
Zhou, J., Ma, X., He, X., Chen, B., Yuan, J., Jin, Z., Li, L., Wang, Z., Xiao, Q., Cai, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215732120 · Cited by 65
Zhou, S., Zhao, X., Yang, Z., Yang, R., Chen, C., Zhao, K., Wang, W., Ma, Y., Zhang, Q., & Wang, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32379 · Cited by 65
Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment
Fouad, S., Wells, O. S., Hill, M. A., & D’Angiolella, V. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01144 · Cited by 67
Cyclin D degradation by E3 ligases in cancer progression and treatment
Qie, S., & Diehl, J. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.012 · Cited by 67
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Wang, Y., Zhou, Y., Yang, L., Lei, L., He, B., Cao, J., & Gao, H. (2023) · Advanced Science · doi:10.1002/advs.202303175 · Cited by 66
Mohan, N., Hosain, S. B., Zhao, J. W., Shen, Y., Luo, X. L., Jiang, J., Endo, Y., & Wu, W. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1624128 · Cited by 64
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 67
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 64
Targeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 74
Zhou, B., Yan, J., Guo, L., Zhang, B., Liu, S., Yu, M., Chen, Z., Zhang, K., Zhang, W., Li, X., et al. (2020) · Theranostics · doi:10.7150/thno.44417 · Cited by 66
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1–PD-L1 axis
Gao, K., Shi, Q., Gu, Y., Yang, W., He, Y., Lv, Z., Ding, Y., Cao, W., Wang, C., & Wan, X. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01097-7 · Cited by 62
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer
Hu, G., He, N., Cai, C., Cai, F., Fan, P., Zheng, Z., & Jin, X. (2019) · Pancreatology · doi:10.1016/j.pan.2019.01.011 · Cited by 61
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 58
Cell Cycle Regulation Meets Tumor Immunosuppression
Li, J., & Stanger, B. Z. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.07.010 · Cited by 64
Sun, W., Zhang, Q., Wang, R., Yang, L., Sun, Y., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648687 · Cited by 62
Self-citationPD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination
Yu, X., Li, W., Liu, H., Wang, X., Coarfa, C., Cheng, C., Yu, X., Zeng, Z., Cao, Y., Young, K. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci160456 · Cited by 61
Ding, X., Zeng, T., Wei, Z., Yu, Z.-Z., Huang, W., Yi, H., Lu, S.-S., Feng, J., Feng, X., Wu, D., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0896 · Cited by 64
Longo, V., Brunetti, O., Azzariti, A., Galetta, D., Nardulli, P., Leonetti, F., & Silvestris, N. (2019) · Cancers · doi:10.3390/cancers11040539 · Cited by 61
Wu, M., Xia, X., Hu, J., Fowlkes, N. W., & Li, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23864-9 · Cited by 61
SPOP mutation induces DNA methylation via stabilizing GLP/G9a
Zhang, J., Gao, K., Xie, H., Wang, D., Zhang, P., Wei, T., Yan, Y., Pan, Y., Ye, W., Chen, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25951-3 · Cited by 62
Self-citationShi, Z., Hu, C., Zheng, X., Sun, C., & Li, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00519-1 · Cited by 65
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 66
SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression
Wang, L., Lin, M., Chu, M., Liu, Y., Ma, J., He, Y., & Wang, Z. P. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102795 · Cited by 61
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
Darga, E. P., Dolce, E. M., Fang, F., Kidwell, K., Gersch, C. L., Kregel, S., Thomas, D. G., Gill, A., Brown, M. E., Gross, S. C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260124 · Cited by 59
CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
Nilmani, D'costa, M., Bothe, A., Das, S., Kumar, S. U., Ramanathan, G., & Doss, C. G. P. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.008 · Cited by 62
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 61
Jin, X., Shi, Q., Li, Q., Zhou, L., Wang, J., Jiang, L., Zhao, X., Feng, K. M., Lin, T., Lin, Z.-H., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0661-z · Cited by 60
Self-citationPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 59
PD-L1 regulation revisited: impact on immunotherapeutic strategies
Lucibello, G., Mograbi, B., Milano, G. A., Hofman, P. M., & Brest, P. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.005 · Cited by 55
Luo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., Raghavendra, A. S., Tripathy, D., Damodaran, S., Hunt, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02226-9 · Cited by 59
Luo, Q., Wu, X., Nan, Y., Chang, W., Zhao, P., Zhang, Y., Su, D., & Liu, Z. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.017 · Cited by 55
Fan, Y., Dan, W., Wang, Y., Ma, Z., Jian, Y., Liu, T., Li, M., Wang, Z., Wei, Y., Liu, B., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.012 · Cited by 55
Self-citationZhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 54
Self-citationSPOP suppresses prostate cancer through regulation of CYCLIN E1 stability
Ju, L., Zhu, Y., Long, Q., Li, X., Lin, X., Tang, S., Yin, L., Xiao, Y., Wang, X., Li, L., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0198-0 · Cited by 54
Self-citationEnhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
Wang, L., Gao, Y., Zhang, G., Li, D., Wang, Z., Zhang, J., Hermida, L. C., He, L., Wang, Z., Si, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2282 · Cited by 60
Self-citationGavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 53
Clinical and genomic features of SPOP‐mutant prostate cancer
Nakazawa, M., Fang, M., Marshall, C. H., Lotan, T. L., Velho, P. I., & Antonarakis, E. S. (2021) · The Prostate · doi:10.1002/pros.24269 · Cited by 55
Wu, D., Li, H., Liu, M., Qin, J., & Sun, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-30707-8 · Cited by 55
Self-citationDegrons: defining the rules of protein degradation
Zhang, Z., Mena, E. L., Timms, R. T., Koren, I., & Elledge, S. J. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00870-z · Cited by 67
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Prestipino, A., & Zeiser, R. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4810 · Cited by 54
Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019) · Journal of Cancer · doi:10.7150/jca.33079 · Cited by 53
Self-citationZhu, Q., Dai, Q., Zhao, L., Zheng, C., Li, Q., Yuan, Z., Li, L., Xie, Z., Qiu, Z., Huang, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06303-z · Cited by 55
McFaline-Figueroa, J. R., Sun, L., Youssef, G., Huang, R. Y., Li, G., Kim, J., Lee, E. Q., Nayak, L., Chukwueke, U. N., Beroukhim, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54326-7 · Cited by 58
Curtaz, C. J., Reifschläger, L., Strähle, L., Feldheim, J., Feldheim, J. J., Schmitt, C., Kiesel, M., Herbert, S.-L., Wöckel, A., Meybohm, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073683 · Cited by 52
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Cancer cell adaptability: turning ribonucleoprotein granules into targets
Lavalée, M., Curdy, N., Laurent, C., Fournié, J., & Franchini, D. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.006 · Cited by 54
ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication
Wang, D., Ma, J., Botuyan, M. V., Cui, G., Yan, Y., Ding, D., Zhou, Y., Krueger, E. W., Pei, J., Wu, X., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd9208 · Cited by 53
Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function
Zhao, X., Wei, Y., Chu, Y., Li, Y., Hsu, J.-M., Jiang, Z., Liu, C., Hsu, J. L., Chang, W., Yang, R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2300 · Cited by 55
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
Liao, H., Chang, X., Gao, L., Ye, C., Qiao, Y., Xie, L., Lin, J., Cai, S., & Dong, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04365-3 · Cited by 55
Romano, S., Tufano, M., D’Arrigo, P., Vigorito, V., Russo, S., & Romano, M. F. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.015 · Cited by 51
A signature of 33 immune‐related gene pairs predicts clinical outcome in hepatocellular carcinoma
Sun, X., Yu, S., Zhang, H., Li, J., Guo, W., & Zhang, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2921 · Cited by 49
Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy
Liu, Q., Aminu, B., Roscow, O., & Zhang, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020791 · Cited by 52
Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia
Gao, X., Qin, S., Wu, Y., Chu, C., Jiang, B., Johnson, R. H., Kuang, D., Zhang, J., Wang, X., Mehta, A. S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143119 · Cited by 48
Self-citationInhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Dang, F., Nie, L., Zhou, J. R., Shimizu, K., Chu, C., Wu, Z., Fassl, A., Ke, S., Wang, Y., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25700-6 · Cited by 52
Self-citationBeyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition
Chaikovsky, A. C., & Sage, J. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0201 · Cited by 50
Huang, D., Montigny, C., Zheng, Y., Beswick, V., Li, Y., Cao, X., Barbot, T., Jaxel, C., Liang, J., Xue, M., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914836 · Cited by 48
Riess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C.-F., Große-Thie, C., Junghanß, C., & Maletzki, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09940-4 · Cited by 47
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 51
Triple-negative breast cancer: new treatment strategies in the era of precision medicine
Wu, S., Wang, H., Shao, Z., & Jiang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1714-8 · Cited by 50
Self-citationTargeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 49
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Rayson, V., Harris, M. A., Savas, P. S., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.008 · Cited by 49
Şahin, T. K., Rizzo, A., Güven, D. C., & Aksoy, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102924 · Cited by 48
Yu, L., Feng, Y., Li, Y.-Y., Zhan, Y., Liu, Y., Yan, H.-M., Fang, Y., Xie, Y., Zhang, F.-J., Chen, L., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz131 · Cited by 47
Patnaik, A., Yap, T. A., Chung, H. C., Miguel, M. J. D., Bang, Y., Lin, C., Su, W., Italiano, A., Chow, K. H., Szpurka, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2821 · Cited by 46
Migliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 50
Jérusalem, G., Prat, A., Salgado, R., Reinisch, M., Saura, C., Ruíz-Borrego, M., Nikolinakos, P. G., Ades, F., Filian, J., Huang, N., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.103580 · Cited by 46
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Chen, X., Wang, K., Jiang, S., Sun, H., 车炫霖, Zhang, M., He, J., Wen, Y., Liao, M., Li, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004026 · Cited by 44
Hou, B., Chen, T., Zhang, H., Li, J., Wang, P., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123244 · Cited by 45
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
Feng, C., Zhang, L., Chang, X., Qin, D., & Zhang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230135 · Cited by 46
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 46
Qian, G., Guo, J., Vallega, K. A., Hu, C.-J., Chen, Z., Deng, Y., Wang, Q., Fan, S., Ramalingam, S. S., Owonikoko, T. K., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0147 · Cited by 43
Self-citationEnhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
Yang, Z., Wang, Y., Liu, S., Deng, W., Lomeli, S. H., Moriceau, G., Wohlschlegel, J. A., Piva, M., & Lo, R. S. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1463 · Cited by 43
Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis
Cheung, A. H. K., Hui, C. H., Wong, K. Y., Liu, X., Chen, B., Kang, W., & To, K. F. (2022) · International Journal of Cancer · doi:10.1002/ijc.34288 · Cited by 47
Frank, S. B., Nelson, P. S., & Vasioukhin, V. I. (2018) · F1000Research · doi:10.12688/f1000research.14499.1 · Cited by 45
Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 43
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2272 · Cited by 43
Rassy, E., Boussios, S., & Pavlidis, N. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13583 · Cited by 42
Zhang, S., You, X.-H., Xu, T., Chen, Q., Li, H., Dou, L., Sun, Y., Xiong, X., Meredith, M. A., & Sun, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05292-9 · Cited by 41
Self-citationTreg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis
Domvri, K., Petanidis, S., Zarogoulidis, P., Anestakis, D., Tsavlis, D., Bai, C., Huang, H., Freitag, L., Hohenforst‐Schmidt, W., Porpodis, Κ., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108620 · Cited by 43
Gao, J., Zhang, H., Zhou, F., Hou, B., Chen, M., Xie, Z., & Yu, H. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.12.009 · Cited by 41
Li, J., Xiao, X., Ou, Y., Cao, L., Guo, M., Qi, C., Wang, Z., Liu, Y., Shuai, Q., Wang, H., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12460 · Cited by 43
Self-citationWang, S., Iyer, R., Han, X., Wei, J., Li, N., Yang, C. H., Zhou, Y., Gao, Q., Zhang, L., Yan, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167728 · Cited by 43
Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus
Wan, Q., Tavakoli, L., Wang, T., Tucker, A. J., Zhou, R., Liu, Q., Feng, S., Choi, D., He, Z., Gack, M. U., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45852-5 · Cited by 41
Zhang, Y., Huang, Y., Yu, D., Xu, M., Hu, H., Zhang, Q., Cai, M., Geng, X., Zhang, H., Xia, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.004 · Cited by 46
Self-citationSTING mediates nuclear PD-L1 targeting-induced senescence in cancer cells
Lee, J., Kim, S. Y., Kim, S. H., Choi, S., Lee, B., & Shin, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05217-6 · Cited by 43
Zhang, H., Chen, H., Yin, S., Fan, L., Jin, C., Zhao, C., & Hu, H. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109186 · Cited by 40
Wang, R., He, S., Long, J., Wang, Y., Jiang, X., Chen, M., & Wang, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00515-5 · Cited by 43
Shu, Z., Dwivedi, B., Switchenko, J. M., Yu, D. S., & Deng, X. (2024) · Nature Communications · doi:10.1038/s41467-024-51242-8 · Cited by 40
Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies
Jia, H., Jiang, L., Shen, X., Ye, H., Li, X., Zhang, L., Hu, Y., Song, D., Jia, H., & Wang, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02397-5 · Cited by 49
Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy
Xu, J., Brosseau, J., & Shi, H. (2020) · Oncogene · doi:10.1038/s41388-020-01491-w · Cited by 41
Mao, L., Dai, J., Cao, Y., Bai, X. L., Sheng, X., Chi, Z., Cui, C., Kong, Y., Zhang, Y., Wu, L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.021 · Cited by 40
Self-citationMechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
Zhang, J., Xu, D., Zhou, Y., Zhu, Z.-F., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676041 · Cited by 40
Self-citationPalicelli, A., Bonacini, M., Croci, S., Magi‐Galluzzi, C., Cañete‐Portillo, S., Chaux, A., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., et al. (2021) · Cells · doi:10.3390/cells10113166 · Cited by 41
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity
Wang, B., Zhou, Y., Zhang, J., Jin, X., Wu, H., & Huang, H. (2019) · Theranostics · doi:10.7150/thno.38137 · Cited by 39
Self-citationPalicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212330 · Cited by 41
Yang, Z., Sun, J. K., Lee, M. M., & Chan, M. K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005068 · Cited by 39
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Ali, L. R., Garrido-Castro, A. C., Lenehan, P. J., Böllenrücher, N., Stump, C. T., Dougan, M. L., Goel, S., Shapiro, G. I., Tolaney, S. M., & Dougan, S. K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220729 · Cited by 40
Metadata
- Authors
- Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., Guo, J., Huang, Y.-H., Fan, C., Ren, S., Sun, Y., Freeman, G. J., Sicinski, P., & Wei, W.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Second Military Medical University (CN)
- Corresponding author
- Freeman, Gordon J.
- Wei, Wenyi
- ORCID
- Venue
- Nature
- Published
- 2017-11-16
- Volume
- 553
- Issue
- 7686
- Pages
- 91-95
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5754234
- OpenAlex
- W2769376007
- Cited by
- 1,013
- References
- 43
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 138 · 2023: 140 · 2022: 134 · 2021: 157 · 2020: 118 · 2019: 78 · 2018: 43
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, R01CA229307, R01CA200573, K99CA212292, R01CA177910, P50CA101942, R01CA132740, R01CA202634, P01CA080111, R01CA200651, R01CA083688)
- National Institute of General Medical Sciences (R01GM094777, R01GM089763)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-L1, anti-PD-1 therapy, CDK4/6 inhibitors, FZR1, proteasomal degradation, polyubiquitination, tumor immune evasion, immune checkpoint blockade, combination immunotherapy, tumor immune microenvironment
- MeSH terms
- Animals, Cell Cycle, Cell Line, Female, Humans, Immunologic Surveillance, Male, Neoplasms, Nuclear Proteins, Phosphorylation, Prostatic Neoplasms, Repressor Proteins, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Cullin Proteins, Proteasome Endopeptidase Complex, 14-3-3 Proteins, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Protein Stability, Cyclin D, Proteolysis, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Cdh1 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
